A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP

Table 1

Demographic and medical characteristics of the study patients.

	TJ-43-treated group (n = 9)	TJ-43-nontreated; group (n = 10)
Sex (male/female)	8/1	7/3
Age (mean ± SD)	63 ± 6.2	68.1 ± 7.3
BMI (mean ± SD)	21.9 ± 1.9	21.2 ± 3.3
Clinical stage
II A	1	1
II B	1	0
III	2	7
IV	5	2
Performance status
0	9	9
1	0	1